Last reviewed · How we verify
Sativex Low Dose
At a glance
| Generic name | Sativex Low Dose |
|---|---|
| Also known as | GW-1000-02 |
| Sponsor | GW Pharmaceuticals Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Pregnenolone as a Treatment for Cannabis Intoxication (PHASE2)
- Cannabinoids as a Treatment for Insomnia in Major Depression (PHASE2)
- Effect of Cannabis on Cigarette Use Behavior (PHASE1)
- A Study Testing the Effects of Different THC Doses on Psychological and Biological Function (PHASE1)
- Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration (PHASE2)
- High Potency Cannabis: Acute and Protracted Effects (PHASE1)
- The Impact of Oral Cannabis Administration and Co-Administration of Alcohol on Impairment (PHASE1)
- Effect of Cannabis Extract on Acute Radicular Pain and on Analgesic Requirement (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sativex Low Dose CI brief — competitive landscape report
- Sativex Low Dose updates RSS · CI watch RSS
- GW Pharmaceuticals Ltd portfolio CI